Combined Flush With Histidine-Tryptophan-Ketoglutarate and University of Wisconsin Solutions in Liver Transplantation: Preliminary Results

Transplant Proc. 2018 Mar;50(2):539-542. doi: 10.1016/j.transproceed.2017.12.033.

Abstract

Introduction: Ischemia reperfusion injury (IRI) is the main cause of early allograft dysfunction (EAD) and subsequent primary allograft failure (PAF).

Objectives: The purpose of this study is to compare IRI, EAD, and PAF in liver transplantation in a cohort of patients perfused with histidine-tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution versus HTK alone.

Methods: A randomized trial was performed to compare outcomes in liver recipients who underwent transplantation surgery in the University Regional Hospital of Malaga, Spain. Forty patients were randomized to two groups. Primary endpoints included IRI, EAD, PAF, re-intervention, acute cellular rejection, retransplantation, arterial complications, and biliary complications at postoperative day 90.

Results: Postoperative glutamic oxaloacetic transaminase (1869.15 ± 1559.75 UI/L vs. 953.15 ± 777.27 UI/L; P = .004) and glutamic pyruvic transaminase (1333.60 ± 1115.49 U/L vs. 721.70 ± 725.02 U/L; P = .023) were significantly higher in patients perfused with HTK alone. A clear tendency was observed in recipients perfused with HTK alone to present moderate to severe IRI (7 patients in the HTK + UW solution group vs. 15 patients in the HTK-alone solution group; P = .06), EAD (0 patients in the HTK + UW solution group vs. 0 patients in the HTK-alone solution group; P = .76), and PAF (3 patients in the HTK + UW solution group vs. 8 patients in the HTK-alone solution group; P = .15).

Conclusions: Initial perfusion with HTK solution followed by UW solution in liver transplantation improves early liver function as compared to perfusion with HTK alone.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adenosine / administration & dosage
  • Adenosine / adverse effects
  • Adult
  • Alanine Transaminase / blood
  • Allopurinol / administration & dosage
  • Allopurinol / adverse effects
  • Aspartate Aminotransferases / blood
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • Glucose / administration & dosage
  • Glucose / adverse effects
  • Glutathione / administration & dosage
  • Glutathione / adverse effects
  • Graft Rejection / chemically induced
  • Humans
  • Insulin / administration & dosage
  • Insulin / adverse effects
  • Liver
  • Liver Transplantation / methods*
  • Male
  • Mannitol / administration & dosage
  • Mannitol / adverse effects
  • Middle Aged
  • Organ Preservation Solutions / administration & dosage*
  • Organ Preservation Solutions / adverse effects
  • Perfusion / adverse effects
  • Perfusion / methods*
  • Postoperative Period
  • Potassium Chloride / administration & dosage
  • Potassium Chloride / adverse effects
  • Procaine / administration & dosage
  • Procaine / adverse effects
  • Raffinose / administration & dosage
  • Raffinose / adverse effects
  • Reoperation
  • Reperfusion Injury / chemically induced
  • Spain
  • Treatment Outcome

Substances

  • Bretschneider cardioplegic solution
  • Insulin
  • Organ Preservation Solutions
  • University of Wisconsin-lactobionate solution
  • Mannitol
  • Procaine
  • Allopurinol
  • Potassium Chloride
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Glutathione
  • Glucose
  • Adenosine
  • Raffinose